Our Medicines – UK

homepage banner

Our Medicines – UK

homepage banner
Please note that this information is specific to the UK and is not intended to replace the advice of a qualified healthcare professional. Chugai is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

Akynzeo ® (palonosetron/netupitant) Hard Capsules

Aloxi ® (palonosetron) Solution for Injection

Granocyte ® (lenograstim) Powder and Solvent for Solution for Injection/Infusion

Hemlibra ® ▼ (emicizumab) 30 mg/mL Solution for Injection

Hemlibra ® ▼ (emicizumab) 150 mg/mL Solution for Injection

RoActemra ® (tocilizumab) Concentrate for Solution for Infusion

RoActemra ® (tocilizumab) Solution for Injection in Pre-Filled Pen

RoActemra ® (tocilizumab) Solution for Injection in Pre-Filled Syringe

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or the Apple App Store. To report an Adverse Reaction directly to Chugai or Roche please see the contact details below or click here for more information.

Report an Adverse Reaction to Chugai Pharma UK Ltd
(for Grancoyte, Aloxi and Akynzeo)
Telephone: +44 (0) 20 8987 5600
Email: [email protected]

Report an Adverse Reaction to Roche Products Ltd
Email: [email protected]

Adverse events for Hemlibra▼ and RoActemra should be reported to Roche Products Ltd. Please contact Roche drug safety centre by emailing Roche. Hemlibra and RoActemra are biological medicines, Healthcare Professionals should report adverse reactions by brand name and batch number.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects.

Roche are the marketing authorisation holders for Hemlibra▼ and RoActemra and Chugai work closely in partnership with Roche to promote these medicines to prescribers. Helsinn are the marketing authorisation holders for Akynzeo and Aloxi and Chugai work closely in partnership with Helsinn to promote these medicines to prescribers.